Security key
29337E102
Enliven Therapeutics, Inc. - COMMON STOCK (ELVN)
CUSIP: 29337E102
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 47,688,348
- Total 13F value
- $1,218,010,157
- Share change
- -836,404
- Put/Call ratio
- 500%
- SEC-reported price per share
- $25.54
- Number of holders
- 100
- Value change
- -$20,810,259
- Number of buys
- 58
- Number of sells
- 33
- Shares outstanding
- 71,310,600
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
100
Top holders
10
ELVN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2024
Previous quarter: Q2 2024
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29337E102
Recent filing periods:
Ownership snapshot
Top reported holders of ELVN - Enliven Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
3/4/5
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
11%
FMR LLC
8%
Venrock Adviser, LLC
5.6%
Commodore Capital LP
5.6%
Fairmount Funds Management LLC
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
11%
|
$186,014,403
7,959,538 shares
|
— | 30 Jun 2024 |
| FMR LLC |
13F
Company
|
8%
|
$133,082,054
5,694,568 shares
|
— | 30 Jun 2024 |
| Venrock Adviser, LLC |
13F
Company
|
5.6%
|
$94,095,355
4,026,331 shares
|
— | 30 Jun 2024 |
| Commodore Capital LP |
13F
3/4/5
Company · 10%+ Owner
|
5.6%
|
$92,854,736
3,973,245 shares
|
— | 30 Jun 2024 |
| Fairmount Funds Management LLC |
13F
Company
|
4.5%
|
$74,849,389
3,202,798 shares
|
— | 30 Jun 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
3.8%
|
$63,818,166
2,730,773 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
100
Shares
47,688,348
Rows available
100
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
91
Q3 2024 holders
100
Holder diff
9
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend